Pfizer's Viagra market share in China challenged by Guangzhou Baiyunshan's 'golden spear'

Jin'ge (Chinese for "golden spear") from China's Guangzhou Baiyunshan is said to be on track to eclipse sales of Pfizer's ($PFE) Viagra in China in a few years with a price that is 60% less than the branded erectile dysfunction drug. The company is also said to be looking at taking the copy international. Before Jin'ge hit the market last year, Viagra reportedly had 60% of the market share and Eli Lilly's ($LLY) Cialis held 34.6%, FiercePharmaAsia reports.

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.